Propranolol Accelerates Adipogenesis in Hemangioma Stem Cells and Causes Apoptosis of Hemangioma Endothelial Cells

Wong, Alvin; Hardy, Krista L.; Kitajewski, Alex; Shawber, Carrie J.; Kitajewski, Jan; Wu, June K.

doi:10.1097/prs.0b013e318267d3db

Cited by 92 publications

(109 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HemSC isolation and characterization were done as previously described (51,52). In brief, proliferating regions of IH tissue were digested with collagenase, and HemSCs were isolated by CD133 + magnetic bead selection (Miltenyi Biotech).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

NOTCH3 regulates stem-to–mural cell differentiation in infantile hemangioma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

“…NCr nude females (strain Foxn1nu) 4-6 weeks old were used (Taconic). The xenograft IH mouse model was performed as previously described (51,52). On day 0, 1.5 × 10 6 HemSCs suspended in 200 μl of Matrigel (Corning) were implanted subcutaneously into 7-to 9-week-old female NCr nude females (Taconic).…”

Section: Methodsmentioning

confidence: 99%

NOTCH3 regulates stem-to–mural cell differentiation in infantile hemangioma

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…The mechanisms whereby propranolol works include vasoconstriction of the high-flow blood vessels feeding the hemangioma, suppression/blockade of VEGF and bFGF with induction of apoptosis of capillary endothelial cells, blockade of GLUT1 receptors, and accelerated adipogenesis of hemangioma stem cells. 9,33,34 Other authors suggest that propranolol does not induce apoptosis of infantile hemangioma stem cells, which is in contrast with the result of capillary endothelial cells. 35 In contrast to corticosteroids, propranolol is effective in treating hemangiomas in children of all ages, and not limited to the proliferative stage of the lesions.…”

Section: Managementmentioning

confidence: 42%

Infantile Hemangioma

Leung¹,

Barankin²,

Hon³

2014

Pediatr Neonatal Nurs Open J

View full text Add to dashboard Cite

Infantile hemangiomas typically appear in the first few weeks of life as areas of pallor, followed by telangiectatic patches. They then grow rapidly in the first 3 to 6 months of life. Superficial lesions are bright red, protuberant, and sharply demarcated and are often referred to as "strawberry hemangiomas". Deep lesions are bluish and dome-shaped, feel like a "bag of worms", and are compressible. Infantile hemangiomas have a predilection for the head and neck region. Most infantile hemangiomas exist as solitary lesions. Infantile hemangiomas continue to grow until 9 to 12 months of age, at which time the growth rate slows down to parallel the growth of the child. Half of these lesions will show complete involution by the time a child reaches age 5; 70% will have disappeared by age 7; and 95% will have regressed by ages 10 to 12. The majority of infantile hemangiomas require no treatment. Indications for active intervention include severe or recurrent hemorrhage unresponsive to treatment, threatening ulceration in areas where serious complications might ensue, interference with vital structures, pedunculated hemangiomas, and significant disfigurement. Treatment options include systemic corticosteroids, intralesional corticosteroids, topical and oral beta blockers, pulsed-dye laser, and less commonly interferon-α or surgical resection. In recent years, propranolol, a nonselective β-blocker, has been preferentially used as a first-line treatment of problematic infantile hemangioma.

show abstract

“…12,13,[20][21][22] Suggested therapeutic mechanism of propranolol was inhibition of angiogenesis and induction of apoptosis in endothelial cells. 23 Propranolol has been used for hemangiomas in our clinic since 2009. Herein we presented the treatment experience with oral propranolol in 27 patients with hemangioma.…”

Section: Discussionmentioning

confidence: 99%

Propranolol as a First-Line Treatment of Infantile Hemangioma: Single Center Experience

Ince¹,

Demirağ²,

Töret³

et al. 2015

Turkiye Klinikleri J Pediatr

View full text Add to dashboard Cite

A AB BS S T TR RA AC CT T OOb bj je ec ct ti iv ve e: : Infantile hemangiomas (IHs) are the most common benign vascular tumors in infancy. Spontaneous regression is expected in majority of IHs, so watchful waiting is the best management. Currently propranolol has taken the place of corticosteroids for the treatment of risky IHs. Herein we aimed to analyze our patients with IHs treated with propranolol. M Ma at te er ri ia al l a an nd d M Me et th h--o od ds s: There were 240 patients with diagnosis of IH, treatment was indicated in 11.3% (n:27) of them, and these 27 patients received propranolol as a first-line treatment between January 2012-January 2015. Medical records of these 27 patients were analized retrospectively. Clinical characteristics, physical examination findings, treatment indications, treatment details, responses and side effects of propranolol were analized retrospectively. R Re es su ul lt ts s: : The median age at diagnosis was 3 months (1-15), and M/F ratio was 0.23. The most common hemangioma localization was skin and head-neck region in 55.6% of patients. Treatment indications were local complications (haemorrhage, ulceration, infection) (44.4%), life threating organ dysfunction (33.3%) and relative indications (22.2%). The median follow-up period was 12 months (1-26 months). Pallor and partially regression in hemangiomas were observed between the fourth and sixth weeks in all patients. Complete remission occured in 15 patients, treatment is going on with partial remission in remaining 12 cases. There was no observed side effects of propranolol. C Co on nc cl lu us si io on n: : Propranolol is a well-tolerated, efficacious, and safe drug for treatment of IHs. It can be initiated and administered in the outpatient setting. Treatment indications of IHs may become more flexible taking into account of the safety profile of propranolol.K Ke ey y W Wo or rd ds s: : Hemangioma, capillary infantile; propranolol; treatment outcome Ö ÖZ ZE ET T A Am ma aç ç: : İnfantil hemanjiyomlar (İH) süt çocukluğu döneminin en sık karşılaşılan benign vasküler tümörleridir. Bu hastaların büyük bölümünde kendiliğinden gerileme beklenmektedir ve bu nedenle izleyerek beklemek en iyi yaklaşımdır. Günümüzde riskli IH tedavisinde kortikosteroidlerin yerini propranolol tedavisi almıştır. Biz burada IH tanısıyla izlediğimiz propranolol tedavisi uyguladığımız hastaları analiz ettik. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Ocak 2012-Ocak 2015 tarihleri arasında İH tanısı almış 240 hasta vardı, bunların %11,3 (n:27)'üne tedavi endikasyonu konmuştu ve ilk sıra tedavide propranolol verilmişti. Bu 27 hastanın tıbbi kayıtları retrospektif olarak incelendi. Klinik karakteristikler, fizik inceleme bulguları, tedavi endikasyonları, tedavi detayları, yanıtlar ve propranolol yan etkileri analiz edildi. B Bu ul lg gu ul la ar r: : Hastaların ortanca tanı yaşı 3 ay (1-15), E/K oranı 0,23 bulundu. Hemanjiyomun en sık lokalizasyonu deri ve baş boyun bölgesiydi (%55,6). Tedavi endikasyonları lokal komplikasyonlar (hemoraji,...

show abstract

Propranolol Accelerates Adipogenesis in Hemangioma Stem Cells and Causes Apoptosis of Hemangioma Endothelial Cells

Cited by 92 publications

References 19 publications

NOTCH3 regulates stem-to–mural cell differentiation in infantile hemangioma

NOTCH3 regulates stem-to–mural cell differentiation in infantile hemangioma

Infantile Hemangioma

Propranolol as a First-Line Treatment of Infantile Hemangioma: Single Center Experience

Contact Info

Product

Resources

About